Enochian Biosciences 

Enochian Biosciences, Inc. engages in the development of genetically modified cellular and immune-therapy technologies for treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 8 full-time employees. The firm focuses on developing vaccine against colorectal cancer. The company has developed various vaccines that are used in various clinical trials in Europe and Asia, including MelCancerVac (MCV) for treatment of cancer (one phase I/II trial in Denmark and two phase II trials in Denmark and Singapore), Tolerogenic (producing immunologic tolerance) dendritic cell (TDC) (pre-clinical stage in Denmark), and Melvaccine (MV), a melanoma cell lysate used as standalone vaccine (pre-clinical state in Denmark). The firm offers MCV platform technology, which is a cellular immunotherapy for treatment of cancer. Also, the Company develops gene therapies for patients with human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS).